Iph4102-201
Web28 sep. 2024 · De 29 ste (a.s.zaterdag) dus de presentatie en updates van Innate Pharma Januari 2024 nog 15,57 . De pipeline staat nu een stuk verder in ontwikkeling . De koers niet EORTC CLTF 2024 MEETING CUTANEOUS LYMPHOMA ST GALLEN, SWITZERLAND September 27, 2024 to September 29, 2024 Updated data from ongoing clinical trial … Web7 jun. 2024 · IPH4102 is a first-in-class anti-KIR3DL2 monoclonal antibody that depletes KIR3DL2-expressing cells through antibody-dependent cell-cytotoxicity and …
Iph4102-201
Did you know?
WebInterpretation IPH4102 is safe and shows encouraging clinical activity in patients with relapsed or refractory cutaneous T-cell lymphoma, particularly those with Sézary syndrome. If confirmed in future trials, IPH4102 could become a novel treatment option for these patients. A multi-cohort, phase 2 trial (TELLOMAK) is underway to confirm Web1 aug. 2024 · IPH4102 is a first-in-class monoclonal antibody targeting KIR3DL2, a cell surface protein that is expressed in cutaneous T-cell lymphoma, and predominantly in its leukaemic form, Sézary syndrome. We aimed to assess the safety and activity of IPH4102 in cutaneous T-cell lymphoma. Methods
WebSézary syndrome (SS), the most aggressive form of cutaneous T-cell lymphoma (CTCL), is characterized by a high expression of the KIR3DL2 receptor. Speaking f... Web12 apr. 2024 · Protocol: IPH4102-201: TELLOMAK: An open label, multi-cohort, multi-center phase II study evaluating the efficacy and safety of IPH4102 alone or in combination with …
WebIPH4102-201: National Competent Authority: Italy - Italian Medicines Agency: Clinical Trial Type: EEA CTA: Trial Status: Ongoing: Date on which this record was first entered in the … Web15 jun. 2024 · IPH4102 is Innate Pharma’s wholly-owned, first-in-class anti-KIR3DL2 humanized therapeutic antibody, designed to trigger immune cell-mediated killing of CTCL cancer cells. 25 patients, with a median age of 71 years old and a median number of four prior systemic treatments, were evaluable for safety (10 dose levels: 0.0001 to 10 mg/kg).
WebBrief Title: IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma Official Title: TELLOMAK: T-cell Lymphoma Anti- KIR3DL2 Therapy . …
Web1 aug. 2024 · IPH4102 is a first-in-class monoclonal antibody targeting KIR3DL2, a cell surface protein that is expressed in cutaneous T-cell lymphoma, and predominantly in its … philip nolan filibuster factsWeb30 okt. 2014 · IPH4102 was effective in autologous killing assays in which it induces NK cell–based lysis of autologous Sézary cells, demonstrating both the functional integrity of … truist bank red bank scWeb15 jun. 2024 · About IPH4102: IPH4102 is a first-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody, designed for treatment of CTCL, an orphan disease. This group of rare cutaneous lymphomas of T... truist bank richlands va phone numberWebBackground: IPH4102 is a first-in-class monoclonal antibody targeting KIR3DL2, a cell surface protein that is expressed in cutaneous T-cell lymphoma, and predominantly in its … philip norman\\u0027s first bookWeb29 nov. 2024 · Aims: Sezary Syndrome (SS) is the most aggressive form of cutaneous T cell lymphoma (CTCL), characterized with high blood involvement and expression o… truist bank rewards portalWeb29 jan. 2024 · Innate Pharma : RECEIVES FDA FAST TRACK DESIGNATION FOR IPH4102 IN RELAPSED OR REFRACTORY SÉZARY SYNDROME MarketScreener INNATE PHARMA RECEIVES FDA FAST TRACK DESIGNATION FOR IPH4102 IN RELAPSED OR REFRACTORY SÉZARY SYNDROME Fast Track designation is … philip norup valeryWeb2 feb. 2024 · IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma (TELLOMAK) Latest version (submitted February 2, 2024) … philip norton twitter